Download Centre

Poster Awards Finalists

  • Interview: Erum Aamir
    Erum Aamir of Loughborough University is a finalist in our Poster Awards Session for her work "Model Based Control of Crystal Size Distribution under Growth, Nucleation and Dissolution Mechanisms".
  • Interview: Ghazala Sadiq
    Ghazala Sadiq of the University of Manchester is a finalist in our Poster Awards Session for her work "API Crystallisation – Conglomerate or compound?"
  • Q&A: Martin Wijaya Hermanto
    Martin is a part of the the Department of Chemical and Biomolecular Engineering at the National University of Singapore and is finalised for his work on the use of FBRM in antisolvent crystallization to achieve consistency in the size distribution of the product crystals.

podcasts_lgPodcast

  • Interview: Dr. Ana Kwokal
    A Research Scientist at Pliva, Dr. Kwokal talks to us about the innovating techniques in the field of Polymorphism and Crystallisation. She discusses her interesting new research into alternative ways of seeding crystallisation and where she sees the industry heading this year.


presentations_lg Top Rated 2009 Presentations



articles_lg Additional Content

  • Business Case for Attending Polymorphism & Crystallisation 2010
    Thinking about attending Polymorphism and Crystallisation 2010? To help provide necessary information to management that P&C 2010 is a worthwhile and value-generating event, we offer some insights…
  • Achieving polymorph selectivity in the crystallization of pharmaceutical solids: Basic considerations and recent advances By Dr Susan M Reutzel-Edens, Research Scientist, Eli Lilly
    Controlling the appearance of crystal polymorphs of pharmaceuticals is essential in developing robust large-scale crystallization processes in the pharmaceutical industry. This review describes many of the thermodynamic and kinetic factors that are important for controlling crystal polymorphism and discusses recent advances in the understanding of the molecular mechanisms of polymorph appearance. Case studies in the development of crystallization processes of pharmaceutical solids, where process analytical technology was applied to resolve the complexities introduced by crystal polymorphism, are discussed.